Lakefront Biotherapeutics
LKFT
Positions held
Your positionsLKFT isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Lakefront Biotherapeutics operates in the biotechnology sector, which is known for its potential to innovate and create groundbreaking therapies, positioning it well for future growth.
- Revenue increased by 87% compared to the prior quarter, reaching $12 million.
- The company's gross margin stands at 24.5%, indicating a solid profitability structure despite recent challenges.
- The biotechnology industry is highly competitive, and Lakefront Biotherapeutics faces significant challenges in maintaining its market position.
- The company reported a trailing P/E ratio of 2.79, which suggests potential undervaluation but also reflects market skepticism about future growth.
- Operating margin expanded to -359.3%, highlighting ongoing operational difficulties.
Fundamentals
| Market cap | $1.93B | Enterprise value | $36.52B | Trailing P/E | 2.81 | Forward P/E | -24.74 |
| PEG | — | Price / book | 10.48 | Beta | 0.06 | Dividend yield | 0.00% |
| Revenue growth | -81.5% | Earnings growth | — | Gross margin | 67.6% | Operating margin | -3.6% |
| Profit margin | 60.2% | ROE | 20.1% | ROA | 9.9% | Debt / equity | 0.00 |
| Current ratio | 32.84 | Free cash flow | $138.21M | Analyst recommendation | none | Mean target | $30.24 |
| 52w high | $36.24 | 52w low | $25.68 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $12.1M | $6.5M | $901M | $71.2M | $65.3M | — |
| Op margin | -359.3% | -982.9% | 84.2% | -58.6% | -87.3% | — |
| Net income | $2.1M | $14.5M | $782M | -$202M | -$106M | — |
| Gross margin | 24.5% | 26.0% | 99.9% | 84.8% | 92.8% | — |
| Gross profit | $3.0M | $1.7M | $900M | $60.3M | $60.6M | — |
| Operating income | -$43.5M | -$63.7M | $759M | -$41.7M | -$57.0M | — |
- Revenue +87% vs prior quarter ($12M vs $6.5M).
- Gross margin 24.5% (was 26% prior quarter).
- Operating margin expanded to -359.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $1.1B | $276M | $240M | $241M |
| Op margin | 45.1% | -68.3% | -36.8% | -54.3% |
| Net income | $321M | $74.1M | $212M | -$218M |
| Gross margin | 97.3% | 87.4% | 100.0% | 100.0% |
| Gross profit | $1.1B | $241M | $240M | $241M |
| Operating income | $501M | -$188M | -$88.3M | -$131M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Lakefront Receives Transparency Notification From Bank of America
2026-10-08 · Lakefront Receives Transparency Notification from Bank of America
2026-10-06 · Acquisition of Own Shares
2026-09-29 · Acquisition of Own Shares
2026-09-23 · Lakefront Biotherapeutics' Gamgertamig Has Meaningful Opportunity in Rare Autoimmune Diseases, RBC Says
2026-09-22 · Acquisition of Own Shares
2026-09-21 · Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig
2026-09-15 · Acquisition of Own Shares
2026-09-08 · Acquisition of Own Shares
2026-09-08 · Lakefront to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
2026-09-04 · ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board
Price (daily)
Full chart · RSI · MACD · patterns